XML 65 R2.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Statements of Earnings (Unaudited) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Income Statement [Abstract]        
Net revenues $ 15,776 $ 14,460 $ 44,542 $ 41,232
Cost of products sold 5,304 4,212 13,652 12,508
Selling, general and administrative 3,569 4,205 10,115 10,897
Research and development 2,319 2,130 6,517 6,017
Acquired IPR&D and milestones 2,680 82 3,751 1,183
Other operating income 0 0 24 0
Total operating costs and expenses 13,872 10,629 34,011 30,605
Operating earnings 1,904 3,831 10,531 10,627
Interest expense, net 667 591 1,972 1,550
Net foreign exchange loss (gain) 20 (3) 47 2
Other expense, net 503 1,159 4,583 3,090
Earnings before income tax expense 714 2,084 3,929 5,985
Income tax expense 526 520 1,511 1,676
Net earnings 188 1,564 2,418 4,309
Net earnings attributable to noncontrolling interest 2 3 8 9
Net earnings attributable to AbbVie Inc. $ 186 $ 1,561 $ 2,410 $ 4,300
Per share data        
Basic earnings per share (in dollars per share) $ 0.10 $ 0.88 $ 1.35 $ 2.41
Diluted earnings per share (in dollars per share) $ 0.10 $ 0.88 $ 1.34 $ 2.41
Weighted-average basic shares outstanding (in shares) 1,769 1,769 1,769 1,769
Weighted-average diluted shares outstanding (in shares) 1,772 1,772 1,772 1,772